Hikma Pharmaceuticals (HIK) Competitors

Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Which has more volatility and risk, HIK or HCM?

Hikma Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Does the media refer more to HIK or HCM?

In the previous week, Hikma Pharmaceuticals had 9 more articles in the media than HUTCHMED. MarketBeat recorded 10 mentions for Hikma Pharmaceuticals and 1 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 0.11 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hikma Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
HUTCHMED	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals have more ownership in HIK or HCM?

42.1% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 36.5% of HUTCHMED shares are held by institutional investors. 30.5% of Hikma Pharmaceuticals shares are held by company insiders. Comparatively, 39.0% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is HIK or HCM more profitable?

Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.71% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	9.45%	12.71%	9.40%
HUTCHMED	-6.87%	-5.71%	-5.90%

Do analysts rate HIK or HCM?

Hikma Pharmaceuticals presently has a consensus price target of GBX 2,627.50, suggesting a potential upside of 46.52%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has stronger earnings & valuation, HIK or HCM?

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.74B	1.33	£353.21M	£101.91	17.60
HUTCHMED	£771.01M	3.42	-£52.98M	-£3.92	-62.02

Summary

Hikma Pharmaceuticals beats HUTCHMED on 13 of the 16 factors compared between the two stocks.